TransMedics price target raised to $105 from $90 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on TransMedics (TMDX) to $105 from $90 and keeps an Overweight rating on the shares. The firm says that over the past couple days, it attended the International Society for Heart and Lung Transplantation conference and received additional details on TransMedics’ next generation devices, upcoming pivotal studies and a couple other key topics. The clinical trials are certainly a large endeavor, though Piper comes away from the conference a little more positive on the potential that OCS can demonstrate superior outcomes to static cold storage. The firm continues to believe that TransMedics is revolutionizing the organ market, which will take time but could meaningfully push the stock higher from here